# US 6,730,512 B2 · Combination immunogene therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,512 B2
- Document ID: US6730512B2
- Status: Granted
- Kind: B2
- Application number: 09/826,025
- Filed: 2001-04-04
- Published: 2002-10-31
- Granted: 2004-05-04
- Earliest claimed: 1997-04-09
- Assignees: AMDL, Inc.
- Inventors: Lung-Ji Chang
- Web page: https://patentgrep.com/patent/US6730512B2

## CPC

- C07K 14/005: from viruses
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10361: Methods of inactivation or attenuation
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides to immunogene therapy protocols for the treatment of tumors. In particular, the present invention provides combinations of immune-modulating proteins that induce systemic immunity against tumors. In addition, the present invention provides humanized animal models suitable for the evaluation of anti-human tumor immunity and permit the identification of combinations of immune-modulating genes which when delivered to human tumor cells induce an effective anti-tumor response, including a systemic anti-tumor response.

## Claims

### Claim 1

An expression vector comprising a polynucleotide sequence encoding a B7-2 protein and at least one additional immune modulating protein.

### Claim 2 (depends on 1)

The expression vector according to claim 1, wherein said at least one additional immune modulating protein is a cytokine protein.

### Claim 3 (depends on 2)

The expression vector according to claim 2, wherein said cytokine protein is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulated factor, interferon-gamma, and tumor necrosis factor-alpha.

### Claim 4 (depends on 2)

The expression vector according to claim 2, wherein said cytokine protein is granulocyte-macrophage colony stimulating factor.

### Claim 5 (depends on 1)

The expression vector according to claim 1, wherein said expression vector is a viral vector.

### Claim 6 (depends on 5)

The expression vector according to claim 5, wherein said viral vector is a retroviral vector.

### Claim 7 (depends on 5)

The expression vector according to claim 5, wherein said viral vector is an adenoviral vector.

### Claim 8 (depends on 1)

The expression vector according to claim 1, wherein said expression vector is encapsulated by, or complexed with, a liposome.
